0000096943-17-000110.txt : 20171002 0000096943-17-000110.hdr.sgml : 20171002 20171002172632 ACCESSION NUMBER: 0000096943-17-000110 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20171002 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20171002 DATE AS OF CHANGE: 20171002 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TELEFLEX INC CENTRAL INDEX KEY: 0000096943 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 231147939 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-05353 FILM NUMBER: 171115454 BUSINESS ADDRESS: STREET 1: 550 E SWEDESFORD RD STREET 2: SUITE 400 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 610-225-6800 MAIL ADDRESS: STREET 1: 550 E SWEDESFORD RD STREET 2: SUITE 400 CITY: WAYNE STATE: PA ZIP: 19087 8-K 1 a10-2x20178xkreneotractclo.htm 8-K Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

    

FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    

Date of Report (Date of Earliest Event Reported)
October 2, 2017

TELEFLEX INCORPORATED
(Exact name of Registrant as Specified in Its Charter)
    
Delaware
1-5353
23-1147939
(State or Other Jurisdiction
of Incorporation or Organization)
(Commission File Number)
(IRS Employer
Identification No.)
    

    
550 East Swedesford Road, Suite 400, Wayne, Pennsylvania
19,087
(Address of Principal Executive Offices)
(Zip Code)
 
 
Registrant’s Telephone Number, Including Area Code
(610) 225-6800


    

Not applicable
(Former Name or Former Address, If Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 2.01.     Completion of Acquisition or Disposition of Assets.
On October 2, 2017, Teleflex Incorporated (the “Company”) completed its previously announced acquisition of NeoTract, Inc. (“NeoTract”), pursuant to that certain Agreement and Plan of Merger (the “Merger Agreement”), dated as of September 4, 2017, by and among the Company, Teleflex Urology Limited, a private limited company incorporate under the laws of Ireland (“Teleflex Urology”), NeoTract and Naples Merger Sub Inc., a wholly-owned subsidiary of the Teleflex Urology (“Merger Sub”). Pursuant to the Merger Agreement, Merger Sub merged with and into NeoTract (the “Merger”), with NeoTract surviving the Merger as a wholly-owned subsidiary of Teleflex Urology.

At the closing, Teleflex Urology paid a purchase price of $725 million in cash, subject to customary purchase price adjustments, and the Merger Agreement provides for additional milestone payments by Teleflex Urology of up to $375 million in the aggregate, which milestone payments are each subject to certain net sales requirements with respect to sales of certain products as further described in the Merger Agreement.

The description of the Merger and the Merger Agreement contained in this Item 2.01 does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, which was filed as Exhibit 2.1 to the Form 8-K filed by the Company with the Securities and Exchange Commission on September 5, 2017, and is incorporated by reference herein.

Item 8.01.     Other Events.

On October 2, 2017, the Company issued a press release announcing the completion of its acquisition of NeoTract, a copy of which is filed as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01.     Financial Statements and Exhibits.

(d)    Exhibits. The following exhibits are filed as part of this report:

99.1    Press Release, dated October 2, 2017.


            
            





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.    
Date: October 2, 2017
TELEFLEX INCORPORATED


By: /s/ James J. Leyden 
Name: James J. Leyden
Title: Vice President, General Counsel and Secretary

EXHIBIT INDEX



 EX-99.1 2 exhibit991to10-2x20178xkre.htm EXHIBIT 99.1 Exhibit




Exhibit 99.1
tfxcorpclr73.jpg

Contact:
 Jake Elguicze
 Treasurer and Vice President of Investor Relations
  610-948-2836
FOR IMMEDIATE RELEASE
October 2, 2017

TELEFLEX INCORPORATED COMPLETES ACQUISITION OF NEOTRACT

Wayne, PA -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies designed to improve the health and quality of people’s lives, announced today the completion of its previously announced acquisition of NeoTract, Inc.

On September 5, 2017, the two companies announced a definitive agreement for Teleflex to acquire NeoTract in a transaction valued at up to $1.1 billion. Under the terms of the agreement, Teleflex acquired NeoTract for an upfront cash payment of $725 million at closing, and has agreed to pay up to an additional $375 million upon the achievement of certain commercial milestones related to sales through the end of 2020.

Founded in 2004, NeoTract is a privately-held medical device company that has developed and commercialized the FDA-cleared UroLift® System, a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH. Performed primarily through a transurethral outpatient procedure, the UroLift® System delivers permanent implants that hold open the urethra, reducing the prostate obstruction without cutting, heating, or removing prostate tissue.

Teleflex will provide additional details on the transaction, including an update to its fiscal year 2017 financial outlook as a result of this transaction, on its third quarter 2017 investor conference call.

ABOUT TELEFLEX INCORPORATED

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation - a relentless pursuit of identifying unmet clinical needs - to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees




worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch® and Weck® - trusted brands united by a common sense of purpose.

ABOUT NEOTRACT, INC.

NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. The company’s initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.





 GRAPHIC 3 tfxcorpclr73.jpg begin 644 tfxcorpclr73.jpg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